PEG-PLGA nanoparticles deposited in <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cenocepacia</i>

Tinatini Tchatchiashvili; Helena Duering; Lisa Mueller-Boetticher; Christian Grune; Dagmar Fischer; Mathias W. Pletz; Oliwia Makarewicz

doi:10.1016/j.jpha.2024.01.007

Volume 14 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(12): 100939

Tinatini Tchatchiashvili, Helena Duering, Lisa Mueller-Boetticher, Christian Grune, Dagmar Fischer, Mathias W. Pletz, Oliwia Makarewicz. PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 100939. doi: 10.1016/j.jpha.2024.01.007

Citation:

Tinatini Tchatchiashvili, Helena Duering, Lisa Mueller-Boetticher, Christian Grune, Dagmar Fischer, Mathias W. Pletz, Oliwia Makarewicz. PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 100939. doi: 10.1016/j.jpha.2024.01.007

Citation:

Tinatini Tchatchiashvili, Helena Duering, Lisa Mueller-Boetticher, Christian Grune, Dagmar Fischer, Mathias W. Pletz, Oliwia Makarewicz. PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia[J]. Journal of Pharmaceutical Analysis, 2024, 14(12): 100939. doi: 10.1016/j.jpha.2024.01.007

PDF( 2493 KB)

PEG-PLGA nanoparticles deposited in Pseudomonas aeruginosa and Burkholderia cenocepacia

doi: 10.1016/j.jpha.2024.01.007

a. Institute of Infectious Disease and Infection Control, Jena University Hospital, Jena, 07747, Germany;
b. Institute of Pharmaceutical Technology and Biopharmacy, Friedrich-Schiller-University Jena, Jena, 07743, Germany;
c. Division of Pharmaceutical Technology and Biopharmacy, Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91058, Germany;
d. FAU NeW-Research Center for New Bioactive Compounds, Erlangen, 91058, Germany

Funds:

The work was financially supported by grants from the German Research Foundation (DFG) (Grant Nos.: PL320/3-2, FI899/4-2, and MU4251/1-2), and the Federal Ministry of Education and Research (BMBF), Germany (Grant No.: 13N15467).

Received Date: Sep. 15, 2023
Accepted Date: Jan. 23, 2024
Rev Recd Date: Jan. 03, 2024
Publish Date: Jan. 26, 2024

Abstract

Abstract

In our prior research, polymer nanoparticles (NPs) containing tobramycin displayed robust antibacterial efficacy against biofilm-embedded Pseudomonas aeruginosa (P. aeruginosa) and Burkholderia cenocepacia (B. cenocepacia) cells, critical pathogens in cystic fibrosis. In the current study, we investigated the deposition of a nanoparticulate carrier composed of poly(d,l-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol)-block-PLGA (PEG-PLGA) that was either covalently bonded with cyanine-5-amine (Cy5) or noncovalently bound with freely embedded cationic rhodamine B (RhB), which served as a drug surrogate. After exposing these NPs to bacteria, we performed cell fractionation and fluorescence analysis, which highlighted the accumulation of Cy5 in the outer membranes (OMs) and the accumulation of RhB in the cytoplasm (CP) of cells. The results indicated that these organic NPs are effective vehicles for targeted antibiotic delivery in bacterial cells, explaining the observed increase in the efficacy of encapsulated tobramycin against biofilms. This work emphasizes the potential of PEG-PLGA-based formulations for advanced drug delivery strategies.
- Polyester,
- Tobramycin,
- Poly(ethylene glycol),
- Antimicrobial activity,
- Cystic fibrosis,
- Bacterial membrane,
- Lipopolysaccharide

FullText(HTML)

References(20)

References

[1]	C. Castellani, A.J.A. Duff, S.C. Bell, et al., ECFS best practice guidelines: The 2018 revision, J. Cyst. Fibros. 17 (2018) 153-178.
[2]	C. Schwarz, C. Grehn, S. Temming, et al., Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting, J. Cyst. Fibros. 20 (2021) 1035-1039.
[3]	J.R. Govan, V. Deretic, Microbial pathogenesis in cystic fibrosis: Mucoid Pseudomonas aeruginosa and Burkholderia cepacia, Microbiol. Rev. 60 (1996) 539-574.
[4]	H. Anwar, M. Dasgupta, K. Lam, et al., Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation, J. Antimicrob. Chemother. 24 (1989) 647-655.
[5]	M. Hogardt, J. Heesemann, Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung, Curr. Top. Microbiol. Immunol. 358 (2013) 91-118.
[6]	L. Zhang, D. Pornpattananangku, C.M. Hu, et al., Development of nanoparticles for antimicrobial drug delivery, Curr. Med. Chem. 17 (2010) 585-594.
[7]	M. Klinger-Strobel, J. Ernst, C. Lautenschlager, et al., A blue fluorescent labeling technique utilizing micro- and nanoparticles for tracking in LIVE/DEAD^® stained pathogenic biofilms of Staphylococcus aureus and Burkholderia cepacia, Int. J. Nanomedicine 11 (2016) 575-583.
[8]	J. Ernst, M. Klinger-Strobel, K. Arnold, et al., Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions, Eur. J. Pharm. Biopharm. 131 (2018) 120-129.
[9]	H.W. Taber, J.P. Mueller, P.F. Miller, et al., Bacterial uptake of aminoglycoside antibiotics, Microbiol. Rev. 51 (1987) 439-457.
[10]	M.P. Mingeot-Leclercq, Y. Glupczynski, P.M. Tulkens, Aminoglycosides: Activity and resistance, Antimicrob. Agents Chemother. 43 (1999) 727-737.
[11]	A.D. Cox, S.G. Wilkinson, Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance, Mol. Microbiol. 5 (1991) 641-646.
[12]	J.J. Lipuma, Update on the Burkholderia cepacia complex, Curr. Opin. Pulm. Med. 11 (2005) 528-533.
[13]	Y. Malinovskaya, P. Melnikov, V. Baklaushev, et al., Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells, Int. J. Pharm. 524 (2017) 77-90.
[14]	M. Holzer, V. Vogel, W. Mantele, et al., Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage, Eur. J. Pharm. Biopharm. 72 (2009) 428-437.
[15]	E. Paredes-Osses, K. Hardie, Cell fractionation of Pseudomonas aeruginosa, Bio. Protoc. 3 (2013), 922.
[16]	M. Danaei, M. Dehghankhold, S. Ataei, et al., Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems, Pharmaceutics 10 (2018), 57.
[17]	N. Gotoh, K. Nagino, K. Wada, et al., Burkholderia (formerly Pseudomonas) cepacia porin is an oligomer composed of two component proteins, Microbiology (Reading) 140 (1994) 3285-3291.
[18]	S.C. Aronoff, F.J. Quinn Jr, R.C. Stern, Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis, Pediatr. Pulmonol. 11 (1991) 289-293.
[19]	M. Vaara, Agents that increase the permeability of the outer membrane, Microbiol. Rev. 56 (1992) 395-411.
[20]	A.M. Sophocleous, Y. Zhang, S.P. Schwendeman, A new class of inhibitors of peptide sorption and acylation in PLGA, J. Control. Release 137 (2009) 179-184.